Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN cohort study in southwest Iran

• Published in: Scientific reports Vol. 11; no. 1; p. 1548
• Main Authors: Kiani, Fatemeh Zeynab, Ahmadi, Ali
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 15.01.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/409; 692/699/1785/4037; Adult; Aged; Blood pressure; Cardiovascular diseases; Chronic obstructive pulmonary disease; Cohort analysis; Cohort Studies; Comorbidity; Cross-Sectional Studies; Depression; Diabetes; Diabetes Mellitus; Disease; Dyslipidemia; Dyslipidemias; Fatty Liver; Female; Forced Expiratory Volume - physiology; Health care; Humanities and Social Sciences; Humans; Hypertension; Iran - epidemiology; Lung - physiopathology; Lung diseases; Male; Metabolic disorders; Metabolic Syndrome; Middle Aged; multidisciplinary; Obstructive lung disease; Patients; Population studies; Prevalence; Pulmonary Disease, Chronic Obstructive - complications; Pulmonary Disease, Chronic Obstructive - epidemiology; Regression analysis; Science; Science (multidisciplinary); Spirometry; Spirometry - methods; Vital Capacity - radiation effects; Iran
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-79707-y

Comorbidities are common in chronic obstructive pulmonary disease (COPD) patients. This study was conducted to determine the prevalence of common comorbidities in patients with COPD compared with people without COPD. This cross-sectional, population-based study was performed on 6961 adults aged 35–70 years enrolled in the Shahrekord PERSIAN cohort study. Data (demographic and clinical characteristics, comorbidities, anthropometric and blood pressure measurements, laboratory, and spirometry tests) collection was performed according to the cohort protocol from 2015 to 2019. In the present study, 215 (3.1%) patients were diagnosed with COPD and 1753 (25.18%) ones with restrictive lung patterns. The mean age of COPD patients was 52.5 ± 9.76 years. 55.8% of patients were male, 17.7% were current smokers and 12.1% had a history of smoking or were former smokers. 5.6% of patients had no comorbidity and 94.5% had at least one comorbidity. The most common comorbidities in COPD patients were dyslipidemia (70.2%), hypertension (30.2%), metabolic syndrome (22.8%), and diabetes (16.7%). The most common comorbidities in individuals with a restrictive spirometry pattern were dyslipidemia (68.9%), metabolic syndrome (27.2%), hypertension (26.1%), depression (17.6%), and fatty liver (15.5%). The logistic regression analysis with 95% confidence interval (95%CI) of odds ratio (OR) showed that comorbidities of chronic lung diseases (OR = 2.12, 95% CI 1.30–3.44), diabetes (OR = 1.54, 95%CI 1.03–2.29), cardiovascular disease (OR = 1.52, 95%CI 1.17–2.43), and hypertension (OR = 1.4, 95%CI 1.02–1.99) were more likely to occur in COPD patients than in healthy individuals. Knowing these prevalence rates and related information provides new insights on comorbidities to reduce disease burden and develop preventive interventions and to regulate health care resources to meet the needs of patients in primary health care.